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is intended to substitute for a clinical end-point and is expected
to predict clinical benefit (or harm or lack of clinical benefit) based
on epidemiologic, therapeutic, pathophysiologic, or other scien-
tific evidence’.1 According to Fleming et al., ‘Any changes induced
in the surrogate end-point by a treatment must accurately reflect
changes in the true end-point’.2 Prentice et al. clarify that a surro-
gate end-point is ‘a response variable for which a test of the null
hypothesis of no relationship to the treatment groups under com-
parison is also a valid test of the corresponding null hypothesis
based on the true end-point’.3
Surrogate markers are quantitatively related to tumour bur-
den in all sites. Ideally, they should not be affected by subclonal
heterogeneity, and they should be assessable even at low tumour
burdens.
Surrogate markers are quantitatively related to tumour bur-
den in all sites. Ideally, they should not be affected by subclonal
heterogeneity, and they should be assessable even at low tumour
burdens. When selecting possible surrogate markers as clinical
trial end-points, investigators should weigh several important cri-
teria in order to collect data that will be relevant and sufficient for
subsequent licensure or registration of the anticancer agent. First,
is the potential surrogate biologically associated with the true
end-point? Second, is the treatment somehow associated with
the potential surrogate end-point? Third, does the potential sur-
rogate mediate the treatment’s effect on the true end-point and
is the potential surrogate biologically associated with the true
end-point?4
Under some circumstances the use of a surrogate end-point
might be misleading. For example, even with known perfect cor-
relation within randomized groups, one cannot rely on the poten-
tial surrogate end-point for valid inference about the true end-
point, because even the direction of their effects could be oppo-
site.5 Thus, even in preliminary trials, investigators should not
base conclusions on potential surrogate end-points if the valida-
tion is based solely on high correlation with the true end-point.
In conclusion, wemust agree on new rules that will allow us to
accept biomarkers at early stages of new drug investigations.
These biomarkers must correspond with some clinically relevant
measure, and their use must comply with the usual statistical
tools acceptable for new drug registration or licensure. The best
sort of trial to select and validate surrogate end-points is a com-
parative prospective trial that (1) determines the mean difference
and variance in the surrogate when the experimental and refer-
ence groups are compared, and (2) predicts the mean difference
and variance in the ideal true end-point when the experimental
and reference groups are compared. Such a trial might not save
time or spare patients, however, compared with a trial based on
conventional end-points.
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Drug development has progressed to the age of individualisation.
Therefore opportunities exist for applying biomarkers in this new
paradigm. Several definitions of relevant terms have been pro-
posed by the Biomarkers Definitions Working Group of the
National Institutes of Health (NIH) and the U.S. Food and Drug
Administration (FDA):
– A biological marker (biomarker) is ‘a characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention’.3
– A clinical end-point is ‘a characteristic or variable that reflects
how a patient feels, functions or survives’.3
– A surrogate end-point4 is ‘a biomarker that is intended to sub-
stitute for a clinical end-point. A surrogate end-point is
expected to predict clinical benefit or harm (or lack of benefit
or harm) based on epidemiologic, therapeutic, pathophysio-
logic, or other scientific evidence . . .Although all surrogate
end-points can be considered biomarkers, it is likely that only
a few biomarkers will achieve surrogate end-point status’.3
Pharmaceutical manufacturers, clinical investigators, and reg-
ulators rely on different types of biomarkers in the context of
drug development. Diagnostic biomarkers provide the means to
define a population with a specific disease. Prognostic biomarkers
correlate with outcomes. For example, over expression of her-2/
neu in breast cancer or epidermal growth factor receptor (EGFR)
expression in colorectal cancer indicates poor prognoses. In addi-
tion, tumour size, often assessed with radiographic tools, is a
prognostic marker because it correlates with outcome. Such prog-
nostic markers are frequently the basis for establishing inclusion
criteria for a clinical trial or for defining a patient population. Pre-
dictive biomarkers define populations that might respond more
favourably to a particular intervention from an efficacy or safety
perspective. They can be used to stratify patients for subgroup
analyses. Surrogates are biomarkers that correlate with clinical
benefit and changes in the marker correlate with alterations in
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outcome. Examples include response rate or progression-free sur-
vival in oncology or bone mineral density in osteoporosis preven-
tion and treatment. If validated, a surrogate may serve as a
primary end-point in a pivotal registration study and could sup-
port conditional (European Union) or accelerated (United States)
approval of an anticancer agent. In general, pharmaceutical firms
should routinely engage in discussions with regulators early in
the drug development process.
The critical path initiative (Fig. 1) of the FDA aims to stimulate
and facilitate a national effort to modernise the scientific process
through which a potential human drug, biological product, or
medical device is transformed from the discovery or proof-of-
concept stage into a standard therapeutic or diagnostic product.
The focus of this initiative is to update the evaluative tools cur-
rently used to assess the safety and efficacy of new medical prod-
ucts, including the validation and use of biomarkers in clinical
trial patient selection and as surrogate end-points.4
CHALLENGES OF USING BIOMARKERS: Regarding the use of bio-
markers many questions remain, among them: How good must
the validation be before a biomarker can serve as a basis for clin-
ical decisions? Is it necessary to validate the technology used to
determine the biomarker and its medical relevance? The FDA is
presently analysing a co-development model by which a drug
could be approved along with the relevant biologic assay. Will
greater market segmentation be the end of the blockbuster busi-
ness model? Cytotoxic oncology agents are used in broad patient
populations, but molecularly targeted therapies would be effec-
tive only for particular subpopulations. How much will validation
cost? Early discussion of biomarkers seemed to indicate that their
use might allow cost savings in clinical trials, but now it appears
that early drug development phase costs might be increased
(Fig. 1).
Several key questions must be answered to exploit the full
potential of biomarkers in drug development from a labelling per-
spective: to what extent do the primary or secondary objectives of
a protocol determine or limit the indicated patient population?
How much influence does the protocol design and analysis have
on the decision to include biomarker information in either sec-
tion ‘Indication’ or section ‘Pharmacodynamics? Answers to
these questions impinge on stratification and pre-specified sub-
group analyses and could affect labelling language.
EXAMPLES OF SUCCESSFUL BIOMARKER DEVELOP-
MENT: Targeted therapy has an effect on the size of clinical stud-
ies and safety databases. Trastuzumab (Herceptin), which binds
Her-2/neu and blocks its function, is an example of an efficacy
target. Validating the target-biomarker-antibody relationship
involved a great deal of effort because the initial diagnostic test
was somewhat ineffective. Once the marker was validated, how-
ever, only patients whose tumours over expressed Her2/neu
(about 20–25% of invasive breast cancers) were enrolled in the
phase III trial. Consequently, only 470 patients were required; if
subjects had been accrued from the general patient population,
an estimated 2200 subjects would have been necessary. Signifi-
cant benefit was demonstrated in 1.6 years of follow-up instead
of about 10 years. The response rate in this subpopulation was
50% compared with about 10% in the overall patient population.1
Also an example of a biomarker used as a safety target exists.
Irinotecan (Campto), which is approved for treating metastatic
colorectal cancer, was found to cause grade 4 neutropenia in
about 8% of the general patient population. Subsequent data have
shown that uridine diphosphate glucuronosyltransferase 1A1
(UGT1A1) affects the drug’s metabolism and, therefore, its toxicity
profile.2 The UGT1A1*28 polymorphism, characterised by an addi-
tional TA repeat in the TATA sequence of the UGT1A1 promoter,
was associated with greater toxicity.2 Consequently, the drug’s
label was modified to reduce the starting dose for patients homo-
zygous for the polymorphism.
In summary, a biomarker and its corresponding assay must be
validated before phase III to be useful in reducing trial size. Effi-
cacy targets might allow patient accrual numbers to be decreased,
but safety targets will not. Safety targets might require additional
subpopulation analyses. The value of interim analysis should not
be overlooked. Although usually conducted when 80% of events
have occurred, carrying out the interim analysis when only 60%
or 70% of events are completed may be of great value. Proper
interim analyses could confer benefit by allowing trials to be con-
cluded earlier, thereby speeding the drug to market and reducing
costs associated with clinical trials.
Fig. 1 – Role of biomarkers in the US FDA’s critical path initiative for drug development.
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